Sera Labs offers 1,500 recombinant proteins

Published: 1-Jun-2010
Research & Development

Including cytokines, growth factors, chemokines, hormones, enzymes and viral antigens

Sera Laboratories International, a UK-based serum specialist, has developed more than 1,500 recombinant proteins for a variety of species including human, mouse, rat, porcine, bovine and chicken. The collection includes cytokines, growth factors, chemokines, hormones, enzymes and viral antigens.

Sera Lab’s recombinant proteins are mainly derived from bacterial systems and also include mammalian, yeast, insect and plant sources. All are rigorously tested to ensure excellent quality and biological activity.

With headquarters and storage in Haywards Heath, West Sussex and a cell culture research facility in France, Sera Lab offers a complete range of animal-based research products from a variety of origins. The company supplies laboratories in more than 30 countries worldwide, either directly or through distributors.

See more

You may also like

Research & Development

Cirena and Epigenica launch technologies to accelerate genome editing and epigenomic research

Read more
Two life sciences companies have announced new technologies designed to address long-standing bottlenecks in genome editing and epigenomic analysis, offering faster timelines and improved reproducibility for researchers in academia and industry

Trending Articles

  1. AdvanCell partners with 48Hour Discovery on peptide-based lead-212 radiotherapeutic The pair will develop a novel peptide-based Lead-212 radiotherapeutic targeting a gastrointestinal cancer with significant unmet need, strengthening AdcanCell's pipeline of differentiated targeted alpha therapies
  2. iXCells and Rosebud Biosciences pair up to advance organoid-based models for rare diseases The expansion of iXCells’ iPSCore platform with integration of 3D human organoid expertise will enable evaluation of drug toxicity and tissue-specific responses, meeting growing demand for scalable, patient-relevant human models to support translational decision-making in drug development
  3. Astoriom appoints Will Edwards as Chief Executive Officer Strategic appointment to support global scale-up of sample management operations
  4. Researchers identify early signs of Parkinson's in the blood Researchers at Chalmers University of Technology have identified early-stage Parkinson’s disease biomarkers detectable in blood, revealing a limited diagnostic window that could enable screening and earlier intervention years before motor symptoms appear
  5. Biosero launches GoSimple™, a standardised automation-ready workcell GoSimple workcells simplify workflows and enhance lab efficiency with selected Sartorius and BD instruments

Upcoming event

High Shear = Mixing Success

19 February 2026 | Virtual See all

You may also like

Research & Development

Cirena and Epigenica launch technologies to accelerate genome editing and epigenomic research

Two life sciences companies have announced new technologies designed to address long-standing bottlenecks in genome editing and epigenomic analysis, offering faster timelines and improved reproducibility for researchers in academia and industry
Research & Development

PSI launches platform to speed up site ID, startup and enrolment in pivotal studies

SYNETIC is designed to speed up site identification, startup and patient enrollment in pivotal clinical trials
Ingredients

Piramal Pharma Solutions introduces tablet-in-capsule capabilities

Enhancing dosing flexibility and patient-centric drug delivery
Research & Development

AdvanCell partners with 48Hour Discovery on peptide-based lead-212 radiotherapeutic

The pair will develop a novel peptide-based Lead-212 radiotherapeutic targeting a gastrointestinal cancer with significant unmet need, strengthening AdcanCell's pipeline of differentiated targeted alpha therapies
Research & Development

Baseline Therapuetics launches to advance GLP-1 Phase III Programme in Alcohol Use Disorder

The clinical-stage biotech has launched to progress BT-001, a once-weekly GLP-1 receptor agonist, into FDA-aligned Phase III trials for alcohol use disorder, with studies planned to begin in 2026
Research & Development

Researchers identify early signs of Parkinson's in the blood

Researchers at Chalmers University of Technology have identified early-stage Parkinson’s disease biomarkers detectable in blood, revealing a limited diagnostic window that could enable screening and earlier intervention years before motor symptoms appear
Research & Development

iXCells and Rosebud Biosciences pair up to advance organoid-based models for rare diseases

The expansion of iXCells’ iPSCore platform with integration of 3D human organoid expertise will enable evaluation of drug toxicity and tissue-specific responses, meeting growing demand for scalable, patient-relevant human models to support translational decision-making in drug development
Subscribe now